{
  "ticker": "LLY",
  "target_date": "2025-01-06",
  "actual_date": "2025-01-06",
  "collected_at": "2025-12-08T11:14:20.791724",
  "price": {
    "open": 777.92,
    "high": 778.96,
    "low": 757.7,
    "close": 759.4354858398438,
    "volume": 3991100,
    "change_1d_pct": -2.16,
    "change_7d_pct": -3.84,
    "change_30d_pct": 1.55
  },
  "technicals": {
    "rsi_14": 40.11,
    "sma_20": 778.46,
    "sma_50": 791.29,
    "macd": -7.361,
    "macd_signal": -7.511,
    "macd_histogram": 0.149,
    "bb_upper": 810.81,
    "bb_lower": 746.1,
    "price_vs_sma20_pct": -2.44,
    "price_vs_sma50_pct": -4.03,
    "volume_ratio": 1.27
  },
  "fundamentals": {
    "market_cap": 891432140800,
    "pe_ratio": 48.72097,
    "forward_pe": 43.883274,
    "price_to_book": 37.43957,
    "price_to_sales": 15.0022745,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.58,
    "pct_from_52w_low": 59.41
  },
  "macro": {
    "spy": {
      "price": 590.19,
      "change_1d_pct": 0.58,
      "change_7d_pct": -0.99
    },
    "vix": {
      "level": 16.04,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.62
    },
    "dollar_index": {
      "level": 108.26
    },
    "gold": {
      "price": 2638.4
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Why 2025 will be an inflection for Novo Nordisk, Eli Lilly's GLP-1s",
      "source": "Yahoo",
      "datetime": 1736186400,
      "summary": "Weight-loss drugs have dominated the pharmaceutical market with their rapid success. Barclays head of European pharmaceuticals research, Emily Field, joins Seana Smith and Brad Smith on Morning Brief to discuss her outlook for the GLP-1 market in 2025: \"In terms of the inflection point for the marke",
      "url": "https://finnhub.io/api/news?id=2cf77ae064988b78708cba347af96e547e84b679e5e7090e34f111137fc40993"
    },
    {
      "headline": "Is Eli Lilly and Company (NYSE:LLY) Among Israel Englander\u2019s Top Stock Picks Heading Into 2025?",
      "source": "Yahoo",
      "datetime": 1736168747,
      "summary": "We recently compiled a list of the Billionaire Israel Englander\u2019s Top 10 Stock Picks Heading Into 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stock picks. Israel Englander has always inspired the investment world by founding a",
      "url": "https://finnhub.io/api/news?id=cae25cf9f6e17bdec456932720f6d996d287717a61009a3428398e441e60fc56"
    },
    {
      "headline": "Healthcare Stocks Are Down and Out. Opportunities Abound.",
      "source": "Yahoo",
      "datetime": 1736164800,
      "summary": "Donald Trump\u2019s election win prompted even more bullishness in a stock market that was already up significantly for the year.  For healthcare investors, though, it represented yet another reason to dump some stock.  Trump\u2019s appointment of industry skeptics like  Robert F. Kennedy Jr.,  alongside broa",
      "url": "https://finnhub.io/api/news?id=5ecfaab583f6fb045d9a38e85ba1f30c96ba7ed3da5389896f8a76e88f3a43da"
    },
    {
      "headline": "Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential",
      "source": "SeekingAlpha",
      "datetime": 1736154000,
      "summary": "Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.",
      "url": "https://finnhub.io/api/news?id=871b8f850271e8941fb1a9beb6c513620f523b7934ebc1a942b6ca85d0cb8305"
    },
    {
      "headline": "Amazon\u2019s Prime Video Acquires Melania Trump Film",
      "source": "Yahoo",
      "datetime": 1736104020,
      "summary": "Amazon.com  Prime Video streaming service has licensed what it said was a documentary about former and future first lady  Melania Trump.  The film is being done with her cooperation, and she will have an executive producer credit on the movie, Amazon said Sunday.  Filming of the \u201cbehind-the-scenes\u201d ",
      "url": "https://finnhub.io/api/news?id=5dc2774aad0eaf522a50e27f742eaebf98fd01afca1a0d0907012561f8c485a1"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470584.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000291/xslF345X05/wk-form4_1734470584.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470498.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000289/xslF345X05/wk-form4_1734470498.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470366.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000287/xslF345X05/wk-form4_1734470366.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470270.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000285/xslF345X05/wk-form4_1734470270.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470180.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000283/xslF345X05/wk-form4_1734470180.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}